[1] |
GOMEZ A, ENMAN Y, PARODIS I. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus:insights from clinical trials and real-world evidence[J]. Patient Relat Outcome Meas, 2023, 14:1-13. DOI: 10.2147/PROM.S369584.
|
[2] |
PONS-ESTEL G J, ALARCÓN G S, SCOFIELD L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus[J]. Semin Arthritis Rheum, 2010, 39(4):257-268. DOI: 10.1016/j.semarthrit.2008.10.007.
|
[3] |
DANCHENKO N, SATIA J A, ANTHONY M S. Epidemiology of systemic lupus erythematosus:a comparison of worldwide disease burden[J]. Lupus, 2006, 15(5):308-318. DOI: 10.1191/0961203306lu2305xx.
|
[4] |
DORIA A, ARIENTI S, RAMPUDDA M, et al. Preventive strategies in systemic lupus erythematosus[J]. Autoimmun Rev, 2008, 7(3):192-197. DOI: 10.1016/j.autrev.2007.11.004.
|
[5] |
DORIA A, ZEN M, CANOVA M, et al. SLE diagnosis and treatment:when early is early[J]. Autoimmun Rev, 2010, 10(1):55-60. DOI: 10.1016/j.autrev.2010.08.014.
|
[6] |
GATTO M, ZEN M, IACCARINO L, et al. New therapeutic strategies in systemic lupus erythematosus management[J]. Nat Rev Rheumatol, 2019, 15(1):30-48. DOI: 10.1038/s41584-018-0133-2.
|
[7] |
GATTO M, KISS E, NAPARSTEK Y, et al. In-/ off-label use of biologic therapy in systemic lupus erythematosus[J]. BMC Med, 2014, 12:30. DOI: 10.1186/1741-7015-12-30.
|
[8] |
THONG B, OLSEN N J. Systemic lupus erythematosus diagnosis and management[J]. Rheumatology:Oxford, 2017, 56(suppl_1):i3-13. DOI: 10.1093/rheumatology/kew401.
|
[9] |
YURKOVICH M, VOSTRETSOVA K, CHEN W J, et al. Overall and cause-specific mortality in patients with systemic lupus erythematosus:a meta-analysis of observational studies[J]. Arthritis Care Res, 2014, 66(4):608-616. DOI: 10.1002/acr.22173.
|
[10] |
|
[11] |
ATISHA-FREGOSO Y, TOZ B, DIAMOND B. Meant to B:B cells as a therapeutic target in systemic lupus erythematosus[J]. J Clin Invest, 2021, 131(12):e149095. DOI: 10.1172/JCI149095.
|
[12] |
DEPASCALE R, GATTO M, ZEN M, et al. Belimumab:a step forward in the treatment of systemic lupus erythematosus[J]. Expert Opin Biol Ther,2021,21(5):563-573.
|
[13] |
MURIMI-WORSTELL I B, LIN D H, NAB H, et al. Association between organ damage and mortality in systemic lupus erythematosus:a systematic review and meta-analysis[J]. BMJ Open, 2020, 10(5):e031850. DOI: 10.1136/bmjopen-2019-031850.
|
[14] |
LEE Y H, SONG G G. Anifrolumab for the treatment of active systemic lupus erythematosus:a meta-analysis of randomized controlled trials[J]. Z Rheumatol, 2021, 80(10):988-994. DOI: 10.1007/s00393-020-00928-7.
|
[15] |
BENGTSSON A A, RÖNNBLOM L. Role of interferons in SLE[J]. Best Pract Res Clin Rheumatol, 2017, 31(3):415-428. DOI: 10.1016/j.berh.2017.10.003.
|
[16] |
SAMOTIJ D, REICH A. Biologics in the treatment of lupus erythematosus:a critical literature review[J]. Biomed Res Int, 2019, 2019:8142368. DOI: 10.1155/2019/8142368.
|
[17] |
LEE W S, AMENGUAL O. B cells targeting therapy in the management of systemic lupus erythematosus[J]. Immunol Med, 2020, 43(1):16-35. DOI: 10.1080/25785826.2019.1698929.
|
[18] |
DORIA A, STOHL W, SCHWARTING A, et al. Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive,hypocomplementemic patients with systemic lupus erythematosus[J]. Arthritis Rheumatol, 2018, 70(8):1256-1264. DOI: 10.1002/art.40511.
|
[19] |
|
[20] |
MA X Y, FU X Y, CUI B B, et al. Telitacicept for recalcitrant cutaneous manifestations of systemic lupus erythematosus:a case report and review of the literature[J]. Tohoku J Exp Med, 2022, 258(3):219-223. DOI: 10.1620/tjem.2022.j074.
|
[21] |
WALLACE D J, STOHL W, FURIE R A, et al. A phase Ⅱ,randomized,double-blind,placebo-controlled,dose-ranging study of belimumab in patients with active systemic lupus erythematosus[J]. Arthritis Rheum, 2009, 61(9):1168-1178. DOI: 10.1002/art.24699.
|
[22] |
NAVARRA S V, GUZMÁN R M, GALLACHER A E, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus:a randomised,placebo-controlled,phase 3 trial[J]. Lancet, 2011, 377(9767):721-731. DOI: 10.1016/s0140-6736(10)61354-2.
|
[23] |
FURIE R, PETRI M, ZAMANI O, et al. A phaseⅢ,randomized,placebo-controlled study of belimumab,a monoclonal antibody that inhibits B lymphocyte stimulator,in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2011, 63(12):3918-3930. DOI: 10.1002/art.30613.
|
[24] |
ZHANG F, BAE S C, BASS D, et al. A pivotal phaseⅢ,randomised,placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China,Japan and South Korea[J]. Ann Rheum Dis, 2018, 77(3):355-363. DOI: 10.1136/annrheumdis-2017-211631.
|
[25] |
STOHL W, SCHWARTING A, OKADA M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus:a fifty-two-week randomized,double-blind,placebo-controlled study[J]. Arthritis Rheumatol,2017,69(5):1016-1027.
|
[26] |
FURIE R, KHAMASHTA M, MERRILL J T, et al. Anifrolumab,an anti-interferon-α receptor monoclonal antibody,in moderate-to-severe systemic lupus erythematosus[J]. Arthritis Rheumatol, 2017, 69(2):376-386. DOI: 10.1002/art.39962.
|
[27] |
FURIE R A, MORAND E F, BRUCE I N, et al.Type Ⅰ interferon inhibitor anifrolumab in active systemic lupus erythematosus(TULIP-1):a randomised,controlled,phase 3 trial[J]. Lancet Rheumatol, 2019, 1(4):e208-219. DOI: 10.1016/S2665-9913(19)30076-1.
|
[28] |
WU D, LI J, XU D, et al.A human recombinant fusion protein targeting B lymphocyte stimulator(BlyS)and a proliferation-inducing ligand(APRIL),telitacicept(RC18),in systemic lupus erythematosus(SLE):results of a phase 2b study[EB/OL].(2019-10-23)[2023-10-16].
|
[29] |
BRUNNER H I, ABUD-MENDOZA C, VIOLA D O, et al.Paediatric Rheumatology International Trials Organisation(PRINTO)and the Pediatric Rheumatology Collaborative Study Group(PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus:results from a randomised,placebo-controlled trial[J]. Ann Rheum Dis, 2020, 79(10):1340-1348. DOI: 10.1136/annrheumdis-2020-217101.
|
[30] |
GINZLER E, GUEDES BARBOSA L S, D'CRUZ D, et al. PhaseⅢ/Ⅳ,randomized,fifty-two-week study of the efficacy and safety of belimumab in patients of black African ancestry with systemic lupus erythematosus[J]. Arthritis Rheumatol, 2022, 74(1):112-123. DOI: 10.1002/art.41900.
|
[31] |
MORAND E F, FURIE R, TANAKA Y, et al. Trial of anifrolumab in active systemic lupus erythematosus[J]. N Engl J Med, 2020, 382(3):211-221. DOI: 10.1056/nejmoa1912196.
|
[32] |
WU D, LI J, XU D, et al. Telitacicept,a human recombinant fusion protein targeting B lymphocyte stimulator(BlyS)and a proliferation-inducing ligand(APRIL),in systemic lupus erythematosus(SLE):results of a phase 3 study[EB/OL].(2022-10-18)[2023-10-16].
|
[33] |
BRUCE I N, O'KEEFFE A G, FAREWELL V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus:results from the Systemic Lupus International Collaborating Clinics(SLICC)Inception Cohort[J]. Ann Rheum Dis, 2015, 74(9):1706-1713. DOI: 10.1136/annrheumdis-2013-205171.
|
[34] |
FURIE R, ROVIN B H, HOUSSIAU F, et al. Two-year,randomized,controlled trial of belimumab in lupus nephritis[J]. N Engl J Med, 2020, 383(12):1117-1128. DOI: 10.1056/NEJMoa2001180.
|
[35] |
FDA approves GSK's BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US[EB/OL]. (2020-12-17)[2023-10-10].
|
[36] |
UROWITZ M B, OHSFELDT R L, WIELAGE R C, et al. Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy:a post hoc longitudinal study[J]. Lupus Sci Med, 2020, 7(1):e000412. DOI: 10.1136/lupus-2020-000412.
|
[37] |
KALUNIAN K C, FURIE R, MORAND E F, et al. A randomized,placebo-controlled phaseⅢ extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus[J]. Arthritis Rheumatol, 2023, 75(2):253-265. DOI: 10.1002/art.42392.
|
[38] |
CHATHAM W W, FURIE R, SAXENA A, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus:results of a phase Ⅱ open-label extension study[J]. Arthritis Rheumatol,2021,73(5):816-825.
|